Automate Your Wheel Strategy on BIIB
With Tiblio's Option Bot, you can configure your own wheel strategy including BIIB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BIIB
- Rev/Share 67.1896
- Book/Share 116.2129
- PB 1.1423
- Debt/Equity 0.39
- CurrentRatio 1.4396
- ROIC 0.0784
- MktCap 19451592000.0
- FreeCF/Share 15.7125
- PFCF 8.4734
- PE 13.1108
- Debt/Assets 0.2362
- DivYield 0
- ROE 0.0897
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BIIB | HSBC Securities | Buy | Hold | -- | $118 | April 28, 2025 |
| Downgrade | BIIB | Argus | Buy | Hold | -- | -- | April 4, 2025 |
| Initiation | BIIB | Bernstein | -- | Market Perform | -- | $160 | Feb. 11, 2025 |
| Downgrade | BIIB | Piper Sandler | Overweight | Neutral | $315 | $138 | Jan. 2, 2025 |
| Downgrade | BIIB | BMO Capital Markets | Outperform | Market Perform | $230 | $164 | Dec. 20, 2024 |
| Downgrade | BIIB | Stifel | Buy | Hold | -- | $175 | Dec. 16, 2024 |
| Resumed | BIIB | BofA Securities | -- | Neutral | -- | $178 | Dec. 10, 2024 |
| Downgrade | BIIB | Jefferies | Buy | Hold | $250 | $180 | Dec. 9, 2024 |
| Resumed | BIIB | Raymond James | -- | Market Perform | -- | -- | Oct. 10, 2024 |
News
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
Published: May 12, 2025 by: Seeking Alpha
Sentiment: Neutral
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Read More
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal.
Read More
BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year.
Read More
Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priya Singhal - Head, Development Robin Kramer - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Tim Anderson - Bank of America Chris Schott - JPMorgan Michael Yee - Jefferies Mike DiFiore - Evercore ISI Terence Flynn - Morgan Stanley Geoff Meacham - Citibank Operator Good morning. My name is Melinda, and I'll be …
Read More
Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Biogen Inc. (BIIB) Q1 Earnings Lag Estimates
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Negative
Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago.
Read More
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
Published: May 01, 2025 by: Reuters
Sentiment: Positive
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs.
Read More
Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Read More
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Published: April 25, 2025 by: Seeking Alpha
Sentiment: Negative
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Read More
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Published: April 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region.
Read More
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
Published: April 15, 2025 by: Reuters
Sentiment: Positive
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease.
Read More
Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Read More
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
Published: April 03, 2025 by: Zacks Investment Research
Sentiment: Neutral
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate.
Read More
Biopharma firms with foreign exposure face disruption as Trump's tariffs loom
Published: March 27, 2025 by: Proactive Investors
Sentiment: Negative
The biopharmaceutical industry is bracing for potential disruptions from proposed tariffs aimed at encouraging companies to move manufacturing operations back to the United States. This week, president Donald Trump suggested that tariffs could be implemented on pharma products made outside the US, with a particular focus on Ireland, where many biopharma companies benefit from favorable tax conditions.
Read More
Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square
Published: March 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass., March 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen's presence in Kendall Square, integrating Biogen's research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.
Read More
Biogen Inc. (BIIB) Stifel 2025 Virtual CNS Forum Conference (Transcript)
Published: March 18, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Company Participants Priya Singhal - Head of Development Conference Call Participants Paul Matteis - Stifel Paul Matteis Great. Good morning, everybody.
Read More
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock?
Read More
Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Neutral
Sales of Biogen's BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is resulting in declining total revenues. Biogen's total revenues declined 2% in 2024.
Read More
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.
Read More
The Nasdaq is Cratering But REGN, BIIB and CSGP Are Up Big Today
Published: March 10, 2025 by: 24/7 Wall Street
Sentiment: Negative
If you're one of the over 4 Million Americans set to retire this year, you may want to pay attention.
Read More
Biogen Stock Is Mutating Into a Value Play
Published: February 20, 2025 by: MarketBeat
Sentiment: Neutral
Biogen Inc. NASDAQ: BIIB has steadily declined since peaking at $468.55 in 2021, as shares are trading down 70.64% from those highs to 12-year lows at $137.33. The medical sector biotechnology company is trading at historically low valuations at a 12.41 price-earnings (P/E) ratio, which is less than half of the industry average P/E of 29.52.
Read More
Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy
Published: February 18, 2025 by: Market Watch
Sentiment: Positive
Stoke will receive $165 million upfront and may get up to $385 million in milestone payments.
Read More
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen's rare disease pipeline and leverages global expertise commercializing high-value, disease-modifying medicines for rare genetic diseases Pivotal Phase 3 EMPEROR study of zorevunersen on track to initiate in Q2 2025 with an anticipated readout in 2H 2027 Stoke to receive $165M upfront, shared development costs and is eligible to receive up to $385M in milestones as well as royalties CAMBRIDGE, Mass. and BEDFORD, Mass.
Read More
Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts
Published: February 13, 2025 by: Benzinga
Sentiment: Positive
On Wednesday, Biogen Inc BIIB reported fourth-quarter adjusted EPS of $3.44, up 17%, beating the consensus of $3.35.
Read More
Biogen's Q4 Earnings & Sales Beat, 2025 EPS Guidance Disappoints
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Neutral
BIIB's Q4 earnings and sales beat estimates. EPS guidance for 2025 falls short of expectations.
Read More
Biogen Inc. (BIIB) Q4 2024 Earnings Call Transcript
Published: February 12, 2025 by: Seeking Alpha
Sentiment: Neutral
Biogen Inc. (NASDAQ:BIIB ) Q4 2024 Earnings Conference Call February 12, 2025 8:30 AM ET Company Participants Tim Power - Head of IR Chris Viehbacher - President and CEO Priya Singhal - Head of Development Mike McDonnell - CFO Conference Call Participants Salveen Richter - Goldman Sachs Michael Yee - Jefferies Tim Anderson - Bank of America Brian Abrahams - RBC Capital Markets Marc Goodman - Leerink Paul Matteis - Stifel Umer Raffat - Evercore ISI Chris Schott - JPMorgan Evan Seigerman - BMO Capital Markets Phil Nadeau - TD Cowen Operator Good morning. My name is Jennifer and I …
Read More
Biogen's stock hit by soft guidance and a decline in sales of MS drugs
Published: February 12, 2025 by: Market Watch
Sentiment: Negative
Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.
Read More
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Published: February 12, 2025 by: CNBC
Sentiment: Neutral
Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth. The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.
Read More
Drugmaker Biogen forecasts 2025 profit below expectations
Published: February 12, 2025 by: Reuters
Sentiment: Negative
Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.
Read More
About Biogen Inc. (BIIB)
- IPO Date 1991-09-17
- Website https://www.biogen.com
- Industry Drug Manufacturers - General
- CEO Mr. Christopher A. Viehbacher
- Employees 7605